총 20건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-25
2 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-07
3 A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease Huntingtons Disease Drug: RO7234292|Drug: Placebo Hoffmann-La Roche Phase 3 2019-01-23
4 Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) Carcinoma, Hepatocellular Drug: lenvatinib|Biological: pembrolizumab|Drug: saline placebo Merck Sharp & Dohme Corp.|Eisai Inc. Phase 3 2018-12-31
5 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) Breast Cancer Biological: Pembrolizumab (K)|Drug: Placebo (P)|Drug: Paclitaxel (X)|Drug: Doxorubicin hydrochloride (A)|Drug: Epirubicin (E)|Drug: Cyclophosphamide (C)|Drug: Endocrine therapy|Radiation: Radiation therapy|Procedure: Surgery Merck Sharp & Dohme Corp. Phase 3 2018-12-27
6 A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma Biological: Bempegaldesleukin|Drug: Sunitinib|Biological: Nivolumab|Drug: Cabozantinib Nektar Therapeutics|Bristol-Myers Squibb Phase 3 2018-12-18
7 Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Hepatitis Delta Virus Drug: Lonafarnib|Drug: Ritonavir|Drug: PEG IFN-alfa-2a|Drug: Placebo Lonafarnib|Drug: Placebo Ritonavir Eiger BioPharmaceuticals Phase 3 2018-12-01
8 A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC Bladder Cancer|Muscle-Invasive Bladder Cancer|BMS-986205 Biological: Nivolumab|Drug: BMS-986205|Drug: Gemcitabine|Drug: Cisplatin|Drug: BMS-986205 Placebo Bristol-Myers Squibb Phase 3 2018-10-12
9 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma Biological: Pembrolizumab|Biological: Placebo|Drug: Cisplatin|Drug: 5-FU|Drug: Oxaliplatin|Drug: Capecitabine|Drug: S-1|Biological: Trastuzumab Merck Sharp & Dohme Corp. Phase 3 2018-10-05
10 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Neoplasms by Site Biological: Nivolumab|Drug: rHuPH20 Bristol-Myers Squibb Phase 1|Phase 2 2018-09-24